Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise
Kuros announces final result of capital increase – total gross proceeds of 16.1 million raised
Kuros announces results of rights offering – capital increase will be implemented
Kuros receives FDA 510(k) clearance for extending commercial indications of MagnetOs Putty in the United States
Kuros reports publication of MagnetOs data demonstrating equivalence to autologous bone in spinal fusion
Kuros reports publication of MagnetOs data demonstrating equivalence to autologous bone in spinal fusion